435 related articles for article (PubMed ID: 21392072)
1. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic management of overactive bladder.
Lam S; Hilas O
Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
[TBL] [Abstract][Full Text] [Related]
5. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
6. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
Kobayashi S; Ikeda K; Miyata K
Life Sci; 2004 Jan; 74(7):843-53. PubMed ID: 14659973
[TBL] [Abstract][Full Text] [Related]
7. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.
Kay GG; Ebinger U
Int J Clin Pract; 2008 Nov; 62(11):1792-800. PubMed ID: 18699842
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Cardozo L; Thorpe A; Warner J; Sidhu M
BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
[TBL] [Abstract][Full Text] [Related]
9. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment.
Maruyama S; Tsukada H; Nishiyama S; Kakiuchi T; Fukumoto D; Oku N; Yamada S
J Pharmacol Exp Ther; 2008 Jun; 325(3):774-81. PubMed ID: 18326811
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Leone Roberti Maggiore U; Salvatore S; Alessandri F; Remorgida V; Origoni M; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1387-408. PubMed ID: 22871042
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
[TBL] [Abstract][Full Text] [Related]
12. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
13. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
14. Update on drugs for overactive bladder syndrome.
Drug Ther Bull; 2007 Jun; 45(6):44-8. PubMed ID: 17583229
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
Ohtake A; Ukai M; Hatanaka T; Kobayashi S; Ikeda K; Sato S; Miyata K; Sasamata M
Eur J Pharmacol; 2004 May; 492(2-3):243-50. PubMed ID: 15178371
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Nazir J; Kelleher C; Aballéa S; Maman K; Hakimi Z; Mankowski C; Odeyemi I
Neurourol Urodyn; 2018 Mar; 37(3):986-996. PubMed ID: 29140559
[TBL] [Abstract][Full Text] [Related]
18. Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
Rangganata E; Widia F; Rahardjo HE
Acta Med Indones; 2020 Jul; 52(3):255-263. PubMed ID: 33020336
[TBL] [Abstract][Full Text] [Related]
19. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
